Genenta Science S.p.A. (GNTA)Healthcare | Biotechnology | Milan, Italy | NasdaqCM
0.70 USD
-0.03
(-3.987%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:59 p.m. EDT
GNTA presents a high-risk opportunity capitalizing on a strategic pivot to defense (€6M Sophia deal, Temferon updates), evidenced by volatility and widened short-term momentum signals, but early-stage biotech fundamentals remain severely deteriorated with negative EPS, high cash burn (-$6.8M operating cash flow), and negative forecasting model direction (-38% drop predicted in next 45 days), rendering it an avoidable long-term hold due to balance sheet strain and lack of reliable earnings. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099894 |
| MSTL | 0.435155 |
| AutoARIMA | 0.441688 |
| AutoETS | 0.441691 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.090 |
| Excess Kurtosis | 0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 34.811 |
| Market Cap | 16,532,587 |
| Forward P/E | -1.08 |
| Beta | 0.71 |
| Website | https://www.genenta.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8128171 |
| Address1 | Via Olgettina No. 58 |
| All Time High | 13.13 |
| All Time Low | 0.59 |
| Ask | 0.7 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 47,920 |
| Average Daily Volume3 Month | 1,070,101 |
| Average Volume | 1,070,101 |
| Average Volume10Days | 47,920 |
| Beta | 0.707 |
| Bid | 0.6672 |
| Bid Size | 1 |
| Book Value | 1.096964 |
| City | Milan |
| Country | Italy |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7008 |
| Current Ratio | 14.155 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7315 |
| Day Low | 0.67 |
| Debt To Equity | 34.811 |
| Display Name | Genenta Science S.p.A |
| Ebitda | -6,575,658 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.61 |
| Enterprise Value | -4,013,603 |
| Eps Forward | -0.65 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.80482 |
| Fifty Day Average Change | -0.10402 |
| Fifty Day Average Change Percent | -0.1292463 |
| Fifty Two Week Change Percent | -81.28171 |
| Fifty Two Week High | 10.0 |
| Fifty Two Week High Change | -9.2992 |
| Fifty Two Week High Change Percent | -0.92992 |
| Fifty Two Week Low | 0.59 |
| Fifty Two Week Low Change | 0.11080003 |
| Fifty Two Week Low Change Percent | 0.18779667 |
| Fifty Two Week Range | 0.59 - 10.0 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,639,578,600,000 |
| Float Shares | 17,915,728 |
| Forward Eps | -0.65 |
| Forward P E | -1.0781538 |
| Free Cashflow | -3,095,756 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.30381 |
| Held Percent Institutions | 0.13606 |
| Implied Shares Outstanding | 23,591,020 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-15 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy. |
| Long Name | Genenta Science S.p.A. |
| Market | us_market |
| Market Cap | 16,532,587 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_282965698 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -6,529,827 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 16,532,586 |
| Number Of Analyst Opinions | 1 |
| Open | 0.7309 |
| Operating Cashflow | -6,867,959 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 39 02 26434681 |
| Pre Market Change | -0.023500025 |
| Pre Market Change Percent | -3.3566668 |
| Pre Market Price | 0.6766 |
| Pre Market Time | 1,776,770,467 |
| Previous Close | 0.7299 |
| Price Hint | 4 |
| Price To Book | 0.63885415 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.898 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0291 |
| Regular Market Change Percent | -3.9868479 |
| Regular Market Day High | 0.7315 |
| Regular Market Day Low | 0.67 |
| Regular Market Day Range | 0.67 - 0.7315 |
| Regular Market Open | 0.7309 |
| Regular Market Previous Close | 0.7299 |
| Regular Market Price | 0.7008 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 48,199 |
| Return On Assets | -0.17671 |
| Return On Equity | -0.38034 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,591,020 |
| Shares Percent Shares Out | 0.0057 |
| Shares Short | 133,286 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 73,856 |
| Short Name | Genenta Science S.p.A. |
| Short Percent Of Float | 0.0063 |
| Short Ratio | 1.22 |
| Source Interval | 15 |
| State | MI |
| Symbol | GNTA |
| Target High Price | 7.007179 |
| Target Low Price | 7.007179 |
| Target Mean Price | 7.007179 |
| Target Median Price | 7.007179 |
| Total Cash | 28,149,190 |
| Total Cash Per Share | 1.193 |
| Total Debt | 7,603,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.202395 |
| Two Hundred Day Average Change | -1.501595 |
| Two Hundred Day Average Change Percent | -0.68180096 |
| Type Disp | Equity |
| Volume | 48,199 |
| Website | https://www.genenta.com |
| Zip | 20,132 |